article thumbnail

IISc researchers find picolinic acid’s broad-spectrum antiviral abilities, scouts for partners in pharma companies

AuroBlog - Aurous Healthcare Clinical Trials blog

The Institute is now looking for partners in pharma companies to pursue further clinical development of the findings. When the compound was tested […]

article thumbnail

Top 10 Clinical Trial Trends for 2024

XTalks

From the continuing trend of the rapid adoption of AI tools to the growing use of real-world evidence (RWE) in regulatory decision-making and a focus on enhancing data integrity, find out how clinical trials will evolve in 2024 to shape the future of medical research. percent from 2023 to 2033.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money.

article thumbnail

Indian healthcare providers and pharma companies speed up to combat TB as drug resistance concerns emerge

AuroBlog - Aurous Healthcare Clinical Trials blog

Indian healthcare providers and pharma companies pace up their efforts with early detection and research for new medicines to combat the spread of tuberculosis as drug resistance concerns emerge. TB is a significant public health threat, with an estimated 10 million annual cases. India shares the highest TB burden with 2.69

article thumbnail

Report urges pharma companies to utilise synthetic data in clinical trials

Pharma Times

Report outlines two cases for using synthetic data in the clinical trial process

article thumbnail

Pharma companies team-up to reduce emissions  

Drug Discovery World

The Task Force will now take collective action to address emissions across three priority areas: supply chains, patient care pathways and clinical trials. The companies will agree on a set of common supplier standards designed to decarbonise the supply chain and will pursue green transportation corridors. Official comments .

article thumbnail

Digital tools driving innovative clinical trials

pharmaphorum

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. Source: Izmailova et al, 2017.